All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML
This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination of HMA, FLT3 inhibitor, and venetoclax is...
Jun 15, 2022
|FLT3-ITD
Gail J. Roboz
"The AML Hub is a trusted, respected, and comprehensive resource where clinicians and researchers interested in AML can confidently learn about the most exciting and novel clinical and biological advances in the field."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.